394 related articles for article (PubMed ID: 31836452)
21. Prediction of in vivo drug-drug interactions from in vitro data : factors affecting prototypic drug-drug interactions involving CYP2C9, CYP2D6 and CYP3A4.
Brown HS; Galetin A; Hallifax D; Houston JB
Clin Pharmacokinet; 2006; 45(10):1035-50. PubMed ID: 16984215
[TBL] [Abstract][Full Text] [Related]
22.
Tseng E; Lin J; Strelevitz TJ; DaSilva E; Goosen TC; Obach RS
Drug Metab Dispos; 2024 Feb; ():. PubMed ID: 38408867
[TBL] [Abstract][Full Text] [Related]
23. Mechanism-based inactivation of cytochrome P-450-3A4 by mifepristone (RU486).
He K; Woolf TF; Hollenberg PF
J Pharmacol Exp Ther; 1999 Feb; 288(2):791-7. PubMed ID: 9918590
[TBL] [Abstract][Full Text] [Related]
24. The use of hepatocytes in evaluating time-dependent inactivation of P450 in vivo.
Zhao P
Expert Opin Drug Metab Toxicol; 2008 Feb; 4(2):151-64. PubMed ID: 18330044
[TBL] [Abstract][Full Text] [Related]
25. Computational prediction of cytochrome P450 inhibition and induction.
Kato H
Drug Metab Pharmacokinet; 2020 Feb; 35(1):30-44. PubMed ID: 31902468
[TBL] [Abstract][Full Text] [Related]
26. Cannabinoid Interactions with Cytochrome P450 Drug Metabolism: a Full-Spectrum Characterization.
Doohan PT; Oldfield LD; Arnold JC; Anderson LL
AAPS J; 2021 Jun; 23(4):91. PubMed ID: 34181150
[TBL] [Abstract][Full Text] [Related]
27. Enzyme Kinetics of Oxidative Metabolism-Cytochromes P450.
Korzekwa K
Methods Mol Biol; 2021; 2342():237-256. PubMed ID: 34272697
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of cytochrome P450 enzymes and uridine 5'-diphospho-glucuronosyltransferases by vicagrel in human liver microsomes: A prediction of potential drug-drug interactions.
Liu S; Wang Z; Chan E; Zhao Y; Kang J; Zhang X; Tian X
Chem Biol Interact; 2022 Jan; 352():109775. PubMed ID: 34910929
[TBL] [Abstract][Full Text] [Related]
29. Static and Dynamic Projections of Drug-Drug Interactions Caused by Cytochrome P450 3A Time-Dependent Inhibitors Measured in Human Liver Microsomes and Hepatocytes.
Tseng E; Eng H; Lin J; Cerny MA; Tess DA; Goosen TC; Obach RS
Drug Metab Dispos; 2021 Oct; 49(10):947-960. PubMed ID: 34326140
[TBL] [Abstract][Full Text] [Related]
30. Usefulness of Two-Compartment Model-Assisted and Static Overall Inhibitory-Activity Method for Prediction of Drug-Drug Interaction.
Iga K; Kiriyama A
Biol Pharm Bull; 2017 Dec; 40(12):2024-2037. PubMed ID: 28993551
[TBL] [Abstract][Full Text] [Related]
31. A Review of CYP-Mediated Drug Interactions: Mechanisms and In Vitro Drug-Drug Interaction Assessment.
Lee J; Beers JL; Geffert RM; Jackson KD
Biomolecules; 2024 Jan; 14(1):. PubMed ID: 38254699
[TBL] [Abstract][Full Text] [Related]
32. Numerical Methods for Modeling Enzyme Kinetics.
Yadav J; Korzekwa K; Nagar S
Methods Mol Biol; 2021; 2342():147-168. PubMed ID: 34272694
[TBL] [Abstract][Full Text] [Related]
33. Multienzyme Kinetics and Sequential Metabolism.
Wienkers LC; Rock BM
Methods Mol Biol; 2021; 2342():89-112. PubMed ID: 34272692
[TBL] [Abstract][Full Text] [Related]
34. Deep Learning Models Compared to Experimental Variability for the Prediction of CYP3A4 Time-Dependent Inhibition.
Fluetsch A; Trunzer M; Gerebtzoff G; Rodríguez-Pérez R
Chem Res Toxicol; 2024 Apr; 37(4):549-560. PubMed ID: 38501689
[TBL] [Abstract][Full Text] [Related]
35. Application of mechanism-based CYP inhibition for predicting drug-drug interactions.
Zhou ZW; Zhou SF
Expert Opin Drug Metab Toxicol; 2009 Jun; 5(6):579-605. PubMed ID: 19466877
[TBL] [Abstract][Full Text] [Related]
36. How Science Is Driving Regulatory Guidances.
Yang X; Fan J; Zhang L
Methods Mol Biol; 2021; 2342():595-629. PubMed ID: 34272707
[TBL] [Abstract][Full Text] [Related]
37. SuperCYPsPred-a web server for the prediction of cytochrome activity.
Banerjee P; Dunkel M; Kemmler E; Preissner R
Nucleic Acids Res; 2020 Jul; 48(W1):W580-W585. PubMed ID: 32182358
[TBL] [Abstract][Full Text] [Related]
38. Metabolic interactions of rosmarinic acid with human cytochrome P450 monooxygenases and uridine diphosphate glucuronosyltransferases.
Kim SB; Kim KS; Kim DD; Yoon IS
Biomed Pharmacother; 2019 Feb; 110():111-117. PubMed ID: 30466000
[TBL] [Abstract][Full Text] [Related]
39. Effects of catalpol on the activity of human liver cytochrome P450 enzymes.
Liu L; Cao X; Li T; Li X
Xenobiotica; 2019 Nov; 49(11):1289-1295. PubMed ID: 30557096
[TBL] [Abstract][Full Text] [Related]
40. Effects of artemisinin antimalarials on Cytochrome P450 enzymes in vitro using recombinant enzymes and human liver microsomes: potential implications for combination therapies.
Ericsson T; Sundell J; Torkelsson A; Hoffmann KJ; Ashton M
Xenobiotica; 2014 Jul; 44(7):615-26. PubMed ID: 24400699
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
